Arnoczky SP, et al
PetersonCTPerez SantiagoJIablokovSNChopraDRodionovDAPetersonSN
Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance
Selemon LD, Goldman-Rakic PS (1999)
A 500 mcg dose of a 90% pure product is not the same as a 500 mcg dose of a 99%+ pure product
The restricted use of mucoadhesive particle systems in the clinic teaches us an important lesson for future inhaled drug development: preclinical and clinical studies should include various cell lines, tissues and disease models that represent the complexity of human lung biology (Fig